LOL, 1vman…what? Seriously?
Lotsa downside?
We are near a 52 week low @ .02.
With an O/S of 176M, ONCX has a market cap of just $3.5M.
ONCX as a bio/pharma, engaged in phase one FDA clinical trials for Cancer treatment should easily sustain a market cap of $100M.
A 2000% gain from these levels would be a market cap of just $70M.
A 2000% potential gain just to get to the PPS to where it should be by conservative estimates?
Lack of volume demonstrates no significant dilution as demonstrated by the refinancing of the notes, predicted by several educated traders.
I have been saying for months that Greenville Health Systems and ONCX CEO Redman hold controlling interest of the company through a combination of common and generic convertible preferreds.
That controlling interest block is roughly 140M.
I knew they couldn’t just dilute shareholders without giving up their controlling interest.
Interest and equity on the notes are deferred until April 2019, which means shareholders can confidently hold and add without fear of any substantial dilution for almost a year.
By then, Prolanta FDA phase one trial results will be public.
If they are negative, everyone loses. Note holders, accredited investors, ONCX officers and shareholders.
Why would note holders agree to accrued interest and equity repayment until after results will be made public?
Its because things are looking good for Prolanta and Oncolix.
Every time someone talks about ONCX downside, I find it as reassurance in my opinion.
People obviously don’t understand the potential.
GLTU, IMO and FWIW.
News 
Market Data 
Discover 
